|
KMID : 1170320180240020001
|
|
Korean Journal of Health Economics and Policy
2018 Volume.24 No. 2 p.1 ~ p.23
|
|
|
Cost-Effectiveness of Personalized Medicine as First-Line Therapy According to EGFR Mutation Status for Advanced Non-small Cell Lung Cancer Using Real-World Data: the Entire Patients data in South Korea
|
|
Lim Eun-A
Choi Sang-Eun
|
|
|
Abstract
|
|
|
Backgrounds Personalized medicine as first-line therapy according to EGFR mutation status was cost-effective compared to the standard chemotherapy in non-small cell lung cancer (NSCLC) patients, but some limitations have been found related to the application of clinical efficacy data based on clinical trials. This study aims to evaluate the cost-effectiveness as a supplementary study to confirm the results from previous studies using real-world data.
Methods: Personalized medicine as first-line therapy according to EGFR mutation status was compared with the standard chemotherapy (cisplatin+pemetrexed) in patients with stage 3b or 4 NSCLC. The study was conducted from the national healthcare system perspective. A Markov model was constructed with one month cycle and 60-month time horizon. The data was obtained from National Health Insurance data Sharing Service (NHISS), including the entire patient data of lung cancer during January 1, 2006 to December 31, 2014 in South Korea.
Results: In the base case analysis, the personalized medicine was cost-effective compared to the standard chemotherapy, with KRW 14,019,081 per QALY gained. One-way sensitivity analyses that the results were most sensitive to medical costs.
Conclusions: The results strongly support the results of the personalized medicine evaluated based on clinical trials.
|
|
|
KEYWORD
|
|
|
Non-small cell lung cancer, Cost-effectiveness, EGFR, Personalized medicine, Real-world data
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|